Press Releases Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
40.2 ^USD	+2.58%		+11.79%	+40.17%

12/04	Oppenheimer Adjusts Revolution Medicines Price Target to $45 From $43, Maintains Outperform Rating	MT
12/04	Needham Adjusts Revolution Medicines' Price Target to $46 From $36, Keeps Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024	02/05	AQ
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins	10/04	AQ
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins	08/04	AQ
Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs	05/04	AQ
Revolution Medicines to Participate in Upcoming Investor Conferences	05/04	AQ
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024	29/03	AQ
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress	27/02	AQ
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024	21/02	AQ
Revolution Medicines to Participate in Upcoming Investor Conferences	02/02	AQ
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference	04/01	AQ
Revolution Medicines Completes Acquisition of EQRx	09/11	AQ
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition	08/11	AQ
Revolution Medicines : RVMD Corporate Presentation	07/11	PU
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress	07/11	AQ
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.	01/11	AQ
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023	01/23/01	AQ
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236	22/23/22	AQ
Revolution Medicines : First-in-Human Phase 1/1b Trial of the First-in-Class Bi-Steric mTORC1 Selective Inhibitor RMC-5552 in Patients with Advanced Solid Tumors	14/23/14	PU
Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting	13/23/13	AQ
Revolution Medicines : Preliminary Safety and Pharmacokinetic Profiles of RMC-6236, a First-in-class, RAS-selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Solid Tumors on the Phase 1 Trial RMC-6236-001	13/23/13	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Press Releases

Filters